Human medicines European public assessment report (EPAR): Itovebi, inavolisib, Status: Opinion
Human medicines European public assessment report (EPAR): Aucatzyl, obecabtagene autoleucel, Status: Opinion
Human medicines European public assessment report (EPAR): Ezmekly, mirdametinib, Status: Opinion
Human medicines European public assessment report (EPAR): Bomyntra, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Rolcya, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Conexxence, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Riulvy, tegomil fumarate, Status: Opinion under re-examination
Human medicines European public assessment report (EPAR): Maapliv, amino acids, Status: Opinion
Summary of opinion: Rezolsta, 22/05/2025 Positive
New treatment for adults with acute lymphoblastic leukaemia